Inhibition of the calcineurin/forkhead box O1/fatty acid binding protein 4 pathway prevents SERCA2 dysfunction-induced foam cell formation and atherosclerosis.

IF 7.7 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Beibei Zhu, Shuangxue Luo, Hang Su, Wanping Zhang, Qingqiu Chen, Yiping Zhang, Chenyuan Liu, Pan Li, Tingting Wang, Xiaoyong Tong, Pingping Hu
{"title":"Inhibition of the calcineurin/forkhead box O1/fatty acid binding protein 4 pathway prevents SERCA2 dysfunction-induced foam cell formation and atherosclerosis.","authors":"Beibei Zhu, Shuangxue Luo, Hang Su, Wanping Zhang, Qingqiu Chen, Yiping Zhang, Chenyuan Liu, Pan Li, Tingting Wang, Xiaoyong Tong, Pingping Hu","doi":"10.1111/bph.70170","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>The cysteine residue 674 (C674) of sarcoplasmic/endoplasmic reticulum Ca<sup>2+</sup> ATPase 2 (SERCA2) is pivotal in maintaining SERCA2 activity. The C674S mutation leads to SERCA2 dysfunction and exacerbates atherosclerosis by inducing endoplasmic reticulum stress and inflammation in bone marrow-derived macrophages (BMDMs) and endothelial cells (ECs). This study aimed to explore if SERCA2 dysfunction aggravates atherosclerosis, by disrupting fatty acid metabolism and promoting the formation of macrophage foam cells.</p><p><strong>Experimental approach: </strong>Heterozygous SERCA2 C674S gene mutation knock-in (SKI) mice were used to simulate SERCA2 dysfunction under pathological conditions. Serum from SKI mice and their littermate wild-type mice were taken for metabolomic testing. The entire aorta and aortic root were isolated for histological analysis. BMDMs were used for protein expression, lipid uptake and accumulation analysis.</p><p><strong>Key results: </strong>In SKI BMDMs, SERCA2 dysfunction induced the expression of calcineurin (CaN), which promoted nuclear translocation of forkhead box O1 (FoxO1) and transcription of its downstream target fatty acid-binding protein 4 (FABP4), leading to increased fatty acid synthesis and foam cell formation. Inhibition of the CaN/FoxO1/FABP4 pathway corrects aberrant lipid metabolism and inhibits the formation of foam cells in SKI BMDMs. Pharmacological interventions targeting either FoxO1 or FABP4, or FABP4 partial deficiency, significantly ameliorated atherosclerosis progression.</p><p><strong>Conclusions and implications: </strong>SERCA2 dysfunction accelerates the progression of atherosclerotic lesions by stimulating the CaN/FoxO1/FABP4 pathway and promoting the formation of foam cells. Our findings highlight the importance of SERCA2 function in the context of atherosclerosis and reveal a novel therapeutic strategy to combat lipid accumulation and atherosclerosis.</p>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":" ","pages":""},"PeriodicalIF":7.7000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bph.70170","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose: The cysteine residue 674 (C674) of sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2 (SERCA2) is pivotal in maintaining SERCA2 activity. The C674S mutation leads to SERCA2 dysfunction and exacerbates atherosclerosis by inducing endoplasmic reticulum stress and inflammation in bone marrow-derived macrophages (BMDMs) and endothelial cells (ECs). This study aimed to explore if SERCA2 dysfunction aggravates atherosclerosis, by disrupting fatty acid metabolism and promoting the formation of macrophage foam cells.

Experimental approach: Heterozygous SERCA2 C674S gene mutation knock-in (SKI) mice were used to simulate SERCA2 dysfunction under pathological conditions. Serum from SKI mice and their littermate wild-type mice were taken for metabolomic testing. The entire aorta and aortic root were isolated for histological analysis. BMDMs were used for protein expression, lipid uptake and accumulation analysis.

Key results: In SKI BMDMs, SERCA2 dysfunction induced the expression of calcineurin (CaN), which promoted nuclear translocation of forkhead box O1 (FoxO1) and transcription of its downstream target fatty acid-binding protein 4 (FABP4), leading to increased fatty acid synthesis and foam cell formation. Inhibition of the CaN/FoxO1/FABP4 pathway corrects aberrant lipid metabolism and inhibits the formation of foam cells in SKI BMDMs. Pharmacological interventions targeting either FoxO1 or FABP4, or FABP4 partial deficiency, significantly ameliorated atherosclerosis progression.

Conclusions and implications: SERCA2 dysfunction accelerates the progression of atherosclerotic lesions by stimulating the CaN/FoxO1/FABP4 pathway and promoting the formation of foam cells. Our findings highlight the importance of SERCA2 function in the context of atherosclerosis and reveal a novel therapeutic strategy to combat lipid accumulation and atherosclerosis.

抑制钙调神经磷酸酶/叉头盒O1/脂肪酸结合蛋白4通路可防止SERCA2功能障碍诱导的泡沫细胞形成和动脉粥样硬化。
背景和目的:肌浆/内质网Ca2+ atp酶2 (SERCA2)的半胱氨酸残基674 (C674)是维持SERCA2活性的关键。C674S突变导致SERCA2功能障碍,并通过诱导骨髓源性巨噬细胞(bmdm)和内皮细胞(ECs)的内质网应激和炎症加剧动脉粥样硬化。本研究旨在探讨SERCA2功能障碍是否会通过破坏脂肪酸代谢和促进巨噬细胞泡沫细胞的形成而加剧动脉粥样硬化。实验方法:采用杂合SERCA2 C674S基因突变敲入(SKI)小鼠模拟病理条件下SERCA2功能障碍。取SKI小鼠及其同窝野生型小鼠血清进行代谢组学检测。分离整个主动脉和主动脉根进行组织学分析。BMDMs用于蛋白表达、脂质摄取和积累分析。关键结果:在SKI bmdm中,SERCA2功能障碍诱导钙调神经磷酸酶(calcalineurin, CaN)的表达,从而促进叉头盒O1 (FoxO1)的核易位及其下游靶脂肪酸结合蛋白4 (FABP4)的转录,导致脂肪酸合成增加和泡沫细胞形成。抑制CaN/FoxO1/FABP4通路可纠正SKI BMDMs异常脂质代谢并抑制泡沫细胞的形成。针对fox01或FABP4或FABP4部分缺乏的药物干预可显著改善动脉粥样硬化的进展。结论和意义:SERCA2功能障碍通过刺激CaN/FoxO1/FABP4通路和促进泡沫细胞的形成来加速动脉粥样硬化病变的进展。我们的研究结果强调了SERCA2功能在动脉粥样硬化中的重要性,并揭示了一种对抗脂质积累和动脉粥样硬化的新治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.40
自引率
12.30%
发文量
270
审稿时长
2.0 months
期刊介绍: The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries. Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues. In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信